Scinai Immunotherapeutics Ltd.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -99.9% over 5Y.
today you would have $0.70▼ -99.9%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $7.12 | $33.45 | $59.50 | $296.00 | |
| P/S | — | 75343.3x | 173451.1x | — | — |
| P/B | — | 12189.9x | 11439.4x | — | — |
| EPS | $0.00 | $0.00 | -$160.00 | -$400.00 | |
| Profit margin | — | -633.64% |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| BBLGBone Biologics Corp | $0.62 | — | 0.3x | — | -54.96% | $1.69M |
| AEMDAethlon Medical Inc | $2.49 | — | 0.2x | — | -160.91% | $1.77M |
| SXTCChina SXT Pharmaceuticals, Inc. | $3.00 | — | 0.1x | — | -27.49% | $1.6M |
| MNDRMobile-health Network Solutions | $1.55 |
Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. It engages in the research and development of IL-17 NanoAb, a VHH-based antibody platform for the treatment of immune-mediated and inflammatory diseases, including psoriasis; and PC111, a human monoclonal antibody for the treatment of pemphigus, Steven Johnson's syndrome, and toxic epidermal necrolysis. The company also offers contract development and manufacturing organization services, such as analytical method development, process development, and cGMP manufacturing of clinical-stage materials to early-stage biotechnology companies. It has collaboration partnerships with Max Planck Society and University Medical Center Gottingen for the development of NanoAb candidates; and Recipharm Israel Ltd for the development of biologics and small-molecule programs. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is based in Jerusalem, Israel.
Company description provided by Yahoo Finance.
| 728.88% |
| — |
| — |
| ROE | — | -102.52% | 48.07% | — | — |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 0.1x |
| — |
| -47.59% |
| $1.85M |
| DCOYDecoy Therapeutics Inc. | $2.90 | 0.0x | 0.4x | — | -827.77% | $1.9M |
| EDVAEndovia Health Sciences, Inc. | $0.31 | — | — | — | — | $1.99M |